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Abstract
CD44, an extracellular matrix (ECM) receptor, has been described as a cancer
stem cell marker in multiple cancers, including head and neck squamous cell car-
cinoma (HNSCC). HNSCC orasphere formation or stemness was characterized
by cleavage of CD44, and thus we hypothesized that this proteolytic processing
may be critical to stemness and tumorigenesis. We tested this hypothesis by
examining the mechanisms that regulate this process in vitro and in vivo, and by
exploring its clinical relevance in human specimens. Sphere assays have been
used to evaluate stemness in vitro. Spheres comprised of HNSCC cells or ora-
spheres and an oral cancer mouse model were used to examine the significance
of CD44 cleavage using stable suppression and inhibition approaches. These
mechanisms were also examined in HNSCC specimens. Oraspheres exhibited
increased levels of CD44 cleavage compared to their adherent counterparts.
Given that disintegrin and metalloproteinase domain-containing protein 17
(ADAM17) is a major matrix metalloproteinase known to cleave CD44, we
chemically inhibited and stably suppressed ADAM17 expression in HNSCC cells
and found that these treatments blocked CD44 cleavage and abrogated orasphere
formation. Furthermore, stable suppression of ADAM17 in HNSCC cells also
diminished tumorigenesis in an oral cancer mouse model. Consistently, stable
suppression of CD44 in HNSCC cells abrogated orasphere formation and inhib-
ited tumorigenesis in vivo. The clinical relevance of these findings was confirmed
in matched primary and metastatic human HNSCC specimens, which exhibited
increased levels of ADAM17 expression and concomitant CD44 cleavage com-
pared to controls. CD44 cleavage by ADAM17 is critical to orasphere formation
or stemness and HNSCC tumorigenesis.
Introduction
Oral cancer is one of the leading causes of death world-
wide, and oral squamous cell carcinoma (OSCC) accounts
for more than 90% of oral malignancies [1]. OSCC, a
subtype of head and neck squamous cell carcinoma
(HNSCC) has a poor 5-year survival rate that has not
improved in decades. This underscores the need to fur-
ther examine its pathogenesis and to identify novel bio-
markers and new therapeutic approaches to treat oral
cancer. Although, smoking, alcohol consumption, and
human papillomavirus (HPV) infection are known risk
factors for oral cancer, other mechanisms that contribute
to its pathogenesis, such as the role of cancer stem cells,
are not completely understood, yet merit further investi-
gation and may possess significant therapeutic promise.
CD44, a cell surface glycoprotein that functions as a
receptor for hyaluronic acid (HA), a component of the
extracellular matrix (ECM), has been identified as a cancer
stem cell marker in many cancer types, including breast,
brain, prostate, and HNSCC [2–5]. In HNSCC, a significant
association was found between CD44 expression and poor
5-year survival rates in patients with SCC of the oro- and
hypopharynx, and larynx [6]. CD44 mediates multiple
effects on cell behavior in part through its ability to interact
with HA [7] and due to the presence of multiple isoforms of
CD44 that arise from N- and O-glycosylation, alternative
splicing, and proteolytic cleavage. These multiple forms of
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CD44 may help explain how this fairly ubiquitous protein
can mediate such an array of interactions [8]. These interac-
tions can affect cell adhesion [4, 5, 9], cell proliferation [10],
cell motility, cell survival [11], cell migration [12], tumor
metastasis [13], chemoresistance [14], and apoptotic and
anoikis resistance [8, 15–17]. Anoikis is a form of apoptotic
cell death triggered by loss of ECM contacts, and anoikis
resistance is a form of survival and anchorage-independent
growth that contributes to tumorigenesis [18–20], including
HNSCC [21–25]. Anchorage-independent growth leads to
sphere formation and these assays have been used to evalu-
ate stemness in vitro [3, 26]. Indeed, these sphere assays have
been used to identify and study cancer stem cells in HNSCC
[27–29]. These studies suggest that CD44 plays an important
role in HNSCC tumor initiation by imparting cells with
enhanced anoikis-resistance properties and/or stemness.
CD44 can undergo proteolytic cleavage or shedding by a
variety of proteases. This cleavage also leads to the release
of its cytoplasmic domain from the membrane into the
cytoplasm. This, in turn, perturbs the interaction between
CD44 and attached protein complexes of the cytoskeleton
and growth factor signaling cascades. Additionally, the
cytoplasmic domain can enter the nucleus and act as a tran-
scription factor, changing the gene expression pattern of
cells [30, 31]. Furthermore, shedding of the ectodomain of
CD44 plays a critical role in tumor cell migration [12, 31].
Several proteases are involved in the proteolytic processing
of CD44, including proteins containing a disintegrin and
metalloprotease domain; namely ADAMs and membrane-
type metalloproteases (MT-MMPs). ADAMs are a family of
cell-surface proteases that are related to MMPs and contain
several functional domains, including a metalloproteinase,
disintegrin, cysteine-rich, and transmembrane domain, as
well as a cytoplasmic tail. Cleavage of CD44 via proteases,
including disintegrin and metalloproteinase domain-
containing protein 17 (ADAM17), is associated with metas-
tasis in OSCC [32, 33]. Thus, the shedding of CD44 can
have important effects on tumor cell behavior; however, its
effects on orasphere formation or stemness have not been
explored. Identification of key mediators of this process
could be used to identify therapeutic targets for the treat-
ment of HNSCC. In this study, we examined the role of
CD44 cleavage in the context of HNSCC orasphere forma-
tion or stemness and tumorigenesis. Our data demonstrate,
for the first time that CD44 cleavage by ADAM17 promotes
stemness and tumorigenesis in HNSCC.
Material and Methods
Institutional review board approval
This study has been approved by and was conducted in
accordance with the regulations set for by the institutional
review board and the committee on the use and care of ani-
mals at the University of Michigan.
Cell lines and culture
Head and neck squamous cell carcinoma cells (UM-SCC-
14A, a gift from Tom Carey, University of Michigan
and HSC-3, a gift from Randy Kramer, University of
California-San Francisco) were maintained in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine
serum, 1% penicillin, and 1% streptomycin in a 5% CO2
atmosphere at 37°C.
Oraspheres and control adherent HNSCC
cells
Anoikis-resistant oraspheres and adherent control HNSCC
(UM-SCC-14A and HSC-3) cells were prepared as previ-
ously reported [19, 24, 25]. These HNSCC oraspheres were
developed by maintaining cells under suspension conditions
on poly-HEMA coated plates (7.5 mg/mL in 95% ethanol,
Sigma-Aldrich, St. Louis, MO) for 6 days. In this assay, cells
that survive anchorage withdrawal form multicellular aggre-
gates or oraspheres [24, 25]. The TAPI2 (ADAM17) inhibi-
tor (EMD Millipore, Billerica, MA) was reconstituted in
water and used in the orasphere assays. G1254023X
(ADAM10 inhibitor) and GW280264X (ADAM10 and
ADAM17 inhibitor) were gifts from Dr. Andreas Ludwig
(Christian-Albrechts-University, Kiel, Germany).
Immunoblot analysis
To evaluate the expression of CD44 and ADAM17 in cell
lysates, cells were washed once with phosphate-buffered
saline and lysed on ice for 30 min in RIPA lysis buffer
(R0278; Sigma-Aldrich) containing 1% protease inhibitor
cocktail (P8340; Sigma-Aldrich). For subcellular localiza-
tion experiments, cytosolic and nuclear fractions from
cells were prepared using the NE-PER nuclear and cyto-
plasmic extraction kit (Pierce, Rockford, IL). To evaluate
the expression levels of CD44 and ADAM17 in tissues,
frozen human HNSCC tissue specimens were obtained
(Proteogenex Inc., Culver City, CA) and analyzed. Tissue
specimens were histologically confirmed to contain over
90% tumor tissue prior to analysis. All tissues were snap
frozen in liquid nitrogen immediately after surgery and
preserved at 80°C. A total of 18 tissues from six patients
(matched normal adjacent tissue, primary tumors, and
metastatic tumors from within the same patients) were
investigated in this study. Tissue specimens were minced
and homogenized in RIPA lysis buffer (R0278; Sigma-
Aldrich) containing 1% protease inhibitor cocktail
(P8340; Sigma-Aldrich) and centrifuged at 15,000g to
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remove insoluble material. Lysates were adjusted for pro-
tein concentration with the bicinchoninic acid (BCA)
protein assay kit (Bio-Rad, Hercules, CA), resolved by so-
diumdodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to Immobilon-P membranes
(Millipore). Blots were probed with a CD44 (SC-7946;
Santa Cruz Biotechnology, Santa Cruz, CA), ADAM17
(SC-13973; Santa Cruz Biotechnology), GAPDH
(CS204254; Millipore) or Histone H3 (05-1341; Milli-
pore) primary antibody, followed by a horseradish peroxi-
dase-conjugated anti-rabbit antibody (SC-2004; Santa
Cruz Biotechnology), then developed with the ECL-Plus
detection system (Pierce). To demonstrate equal protein
loading, membranes were stripped and reprobed with an
anti-b-actin antibody (SC-1615; Santa Cruz Biotechnol-
ogy). All other reagents were from Sigma.
Development of stable cell lines
UM-SCC-14A cells were transduced with ADAM17-shRNA
(SC-36604-V), CD44-shRNA (SC-29342-V), or scrambled-
shRNA (SC-108080; Santa Cruz Biotechnology) lentiviral
particles in 0.5 mL of serum-free media, and then selected
in 10 lg/mL puromycin (sc-108071; Santa Cruz Biotech-
nology) for an additional 10 days. Surviving cell colonies
were picked and propagated before testing for ADAM17
and CD44 expression using Western blot analysis.
Immunodeficient oral cancer mouse
xenograft model
To validate the significance of ADAM17 and CD44 in reg-
ulating orasphere formation or stemness and tumorigene-
sis in vivo, HNSCC cells that exhibited stably suppressed
levels of ADAM17 or CD44 and control transduced cells
were tested in an oral cancer mouse model as described
earlier [25, 34, 35]. For these experiments, HNSCC cells
with and without altered ADAM17 and CD44 levels were
suspended in DMEM, chilled on ice, and resuspended in
an equal volume of growth factor reduced Matrigel (BD
Biosciences, San Jose, CA) to a final concentration of
1 9 106 cells/0.05 mL prior to injection. A total volume
of 0.05 mL was injected sub-mucosally into the floor of
the mouth. Six weeks after injection, mice were euthanized
and tumor incidence and/or volume were evaluated as
previously described [25, 34, 35].
Statistical analysis
In general, values are expressed as means  SD. Inter-
group differences were determined by two-way analysis of
variance and Scheffe’s multiple-comparison test. Statistical
significance was defined as P ≤ 0.05. All experiments were
repeated at least three times. For the in vivo studies, inde-
pendent t-tests with unequal variances were used.
Results
CD44 cleavage is a signature of orasphere
formation or stemness
To determine the role of CD44 in orasphere formation or
stemness, we examined the expression of CD44 in ora-
spheres and control/adherent HNSCC cells (UM-SCC-
14A and HSC-3). As reported in our previous publication
[24, 25], when HNSCC cells become anoikis resistant they
form multicellular aggregates or oraspheres in suspension
conditions. This ability to form spheres in suspension is
used as a measure of stemness. We found that as HNSCC
cells formed oraspheres they exhibited CD44 cleavage
(Fig. 1A). This proteolytic processing of CD44 led to high
levels of a small molecular weight fragment of ~25 kDa
that was identifiable by Western blotting. Adherent con-
trol cells did not reveal comparable cleavage. Given that
cleavage products of CD44 can localize to the nucleus
and mediate signaling events, we investigated the subcel-
lular localization of the CD44 cleaved fragments by Wes-
tern blotting. We found that the major cleaved fragment
of CD44 (~25 kDa) is exclusively found in the cytosolic
fraction (Fig. 1B).
ADAM17 mediates cleavage of CD44 and
thereby promotes orasphere formation or
stemness
To specifically explore the role of CD44 cleavage in the pro-
cess of orasphere formation, we inhibited major matrix me-
talloproteinases responsible for CD44 cleavage, namely
ADAM10 and ADAM17. An ADAM17 inhibitor (TAPI2),
inhibited CD44 cleavage in HNSCC cells and prevented
orasphere formation (Fig. 2A and B), supporting the con-
cept that ADAM17-mediated cleavage of CD44 regulates
HNSCC cell stemness. However, an ADAM10 inhibitor
(G1254023X) exhibited lesser effects on orasphere forma-
tion and cleavage of CD44. In addition, stable suppression
of ADAM17 in HNSCC cells once again inhibited CD44
cleavage and prevented orasphere formation or stemness
(Fig. 3A–C). In contrast, control transduced cells in sus-
pension conditions continued to show pronounced cleav-
age of CD44 and orasphere formation.
Stable suppression of ADAM17 in HNSCC
cells reduces tumor burden in vivo
To confirm the importance of ADAM17 in promoting
stemness and thereby tumorigenesis in vivo, HNSCC cells
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A B
Figure 1. Head and neck squamous cell carcinoma (HNSCC) cell oraspheres in suspension exhibit greater levels of CD44 cleavage. (A) (left)
Phase-contrast images of UM-SCC14A and HSC-3 cells under adherent and suspension conditions (Sus/Oras) and (right) immunolots showing the
levels of CD44 expression in UM-SCC14A and HSC-3 cells in adherent (Adh) and suspension conditions (Sus/Oras). (B) Immunolot showing the
levels of CD44 expression in cytosolic and nuclear fractions in UM-SCC14A cells cultured under suspension conditions. GAPDH and Histone H3
served as cytosolic and nuclear markers, respectively. b-actin served as loading control.
A B
Figure 2. Inhibiting CD44 cleavage with a chemical inhibitor of ADAM17 (TAPI2) abrogates orasphere formation in UM-SCC14A cells. (A) Phase-
contrast images of UM-SCC 14A cells cultured under suspension conditions. Cells were either untreated (control) or pretreated with an ADAM10
(G1254023X) or ADAM17 (TAPI2) chemical inhibitor for 2 h and continuously cultured under suspension conditions for 1 day. (B) Immunoblot
showing the levels of CD44 expression in untreated control cells (under adherent or suspension conditions) and cells treated with inhibitors to
ADAM10 (G1254023X), ADAM17 (TAPI2), or ADAM10 and 17 (GW280264X) under suspensions conditions.
A B
C
Figure 3. ADAM17 suppression blocks orasphere formation and inhibits CD44 cleavage in UM-SCC14A cells. (A) Immunoblots showing the levels
of ADAM17 expression in cells transduced with scr-shRNA or ADAM17-shRNA. Three different clones are shown. (B) Phase-contrast images of
cells stably transduced with scr-shRNA or ADAM17-shRNA then cultured under adherent or suspension conditions (Orasphere) for 6 days.
(C) Immunoblots showing the levels of CD44 and ADAM17 expression in cells transduced with scr-shRNA or ADAM17-shRNA and grown under
adherent and suspension conditions as in B.
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with stably suppressed levels of ADAM17 or control
transduced cells, both grown under adherent conditions,
were injected into a floor-of-mouth oral cancer mouse
model. Injection of HNSCC cells with stably suppressed
levels of ADAM17 led to significantly reduced tumor vol-
umes and incidence (Fig. 4A and B; Table 1). In contrast,
injection of control transduced cells led to higher tumor
volumes and incidence. As shown in the graph in Fig-
ure 4, only 5/9 (56%) mice developed tumors when
injected with HNSCC cells that exhibited stable suppres-
sion of ADAM17, whereas 5/7 (71%) mice developed
tumors when injected with HNSCC cells derived from
control transduced cells expressing normal levels of
ADAM17. Of the tumors that did develop in mice
injected with the HNSCC cells with stably suppressed lev-
els of ADAM17, the mean tumor volume was only
29.8 mm3, whereas the tumors in mice injected with con-
trol transduced cells reached a mean tumor volume of
117.8 mm3. Thus, ADAM17 is a critical determinant of
HNSCC tumorigenesis.
CD44 downregulation inhibits orasphere
formation or stemness in vitro and
tumorigenesis in vivo
It stands to reason that while inhibiting cleavage of CD44
can inhibit orasphere formation, loss of CD44 would sim-
ilarly impair this process. Thus, to further elucidate the
importance of CD44 in mediating stemness in HNSCC,
we performed orasphere assays with HNSCC cells exhibit-
ing stably suppressed levels of CD44. As expected, stable
suppression of CD44 expression in HNSCC cells inhibited
orasphere formation (Fig. 5A and B), underscoring the
important role of CD44 in this process. Similarly, we sur-
mised that suppressing stemness by stably suppressing
CD44 would also impair tumorigenesis. Thus, to further
confirm the role of CD44 in modulating stemness and
HNSCC tumorigenesis in vivo, we again used the murine
floor-of-mouth model that mimics human HNSCC. In
agreement with in vitro findings, our mouse model data
showed that suppression of CD44 in HNSCC cells signifi-
cantly reduced tumor incidence in vivo (Fig. 5C). As
shown in the graph in Figure 5C, only 1/6 (17%) of mice
developed tumors when injected with HNSCC cells that
exhibited stable suppression of CD44 (adherent), whereas
2/6 (33%) of mice developed tumors when injected with
HNSCC cells expressing normal levels of CD44 (adher-
ent). Thus, these data further confirm the importance of
CD44 in stemness and tumorigenesis, and that oraspheres
and the stemness phenotype within, is an important func-
tional feature underlying tumorigenesis.
ADAM17 expression and CD44 cleavage are
concomitantly elevated in human HNSCC
tissue specimens
The clinical relevance of these findings was examined in
matched sets of human HNSCC tissue specimens. Specifi-
cally, we examined normal adjacent tissue, primary
A B
Figure 4. ADAM17 suppression reduces tumor burden in vivo. (A) Images show the dissected tumors and (B) percentage of tumor incidence in
mice that were injected with UM-SCC-14A cells that had been transduced with scrambled shRNA or ADAM17 shRNA and grown under adherent
conditions (*P ≤ 0.05).
Table 1. Tumor volumes for mice injected with UM-SCC-14A cells.
Animal
Scr-shRNA ADAM17-shRNA
Tumor volume (mm3) Tumor volume (mm3)
1 101 64
2 137 32
3 136 20
4 127 17
5 88 16
6 No tumor No tumor
7 No tumor No tumor
8 No tumor
9 No tumor
Mean volume 117.8  19 29.8  18*
Statistical analysis: Independent t-test with unequal variances *P ≤
0.01.
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tumors, and metastatic tumors from within the same
patients. The clinical characteristics of the specimens are
reported in Table 2. The tumor specimens were all
advanced stage IV tumors, with a T2–T4 and N1–N2 pro-
file and metastatic lesions to the lymph nodes. The
majority of the tumors exhibited a poorly differentiated
histological grade 3 profile. The data showed that the
primary and metastatic tumor samples exhibited increased
levels of ADAM17 expression and concomitant CD44
cleavage compared to normal controls (Fig. 6). These data
support the concept that ADAM17-mediated cleavage of
CD44 is an important determinant of the stemness
phenotype that promotes HNSCC tumorigenesis.
Discussion
Sphere assays have been used to measure anchorage-
independent growth, anoikis resistance, and recently
stemness [27–29, 36], and thus these processes can be
considered somewhat synonymous. Interestingly,
although sphere assays and the processes of anchorage-
independent growth and anoikis resistance have been
studied for a long time in the context of tumorigenesis
[18] and the ECM, it is only recently that this property
of growing tumor cells in low attachment conditions or
three-dimensional matrices has been rediscovered and
used to evaluate stemness. Indeed as early as 1974, it was
recognized that anchorage-independent growth in vitro in
the form of spherical colonies in semisolid medium can
predict neoplastic growth in nude mice [37]. Also, other
early studies with a focus on the role of the ECM have
provided significant understanding about the properties
regulating these sphere assays. Work by Kantak et al. [19]
demonstrated that E-cadherin expression is critical to
HNSCC sphere formation. Similarly, work by Zhang and
colleagues, showed that a fibronectin ECM provides focal
adhesion kinase (FAK)-mediated survival signals that pro-
mote HNSCC sphere formation [24]. Thus, a discussion
on stemness as evaluated by sphere assays by necessity
should incorporate studies and findings relevant to
anchorage-independent growth and anoikis resistance of
tumor cells.
With this in mind, a brief discussion on anoikis resis-
tance as pertains to tumorigenesis is presented. Cancer
cells that acquire malignant potential have developed
mechanisms to resist anoikis, thereby allowing survival of
cancer cells in systemic circulation and facilitating
secondary tumor formation in distant organ sites [38].
Anoikis resistance is implicated in different human malig-
nancies, including ovarian [39], breast [40], colon [41],
and oral cancer [21]. Several signaling pathways have
been reported to regulate anoikis, whereby involvement
A B C
Figure 5. CD44 suppression inhibits orasphere formation in vitro and reduces tumor incidence in vivo. (A) Immunoblots showing the levels of
CD44 in cells transduced with scrambled shRNA or CD44-shRNA. (B) Phase-contrast images of cells stably transduced with scr-shRNA or CD44-
shRNA then cultured under adherent or suspension conditions (Orasphere) for 6 days. (C) Percentage of tumor incidence in mice that were
injected with UM-SCC-14A cells transduced with scrambled shRNA controls or CD44 shRNA and grown under adherent conditions (*P ≤ 0.05).
Table 2. Clinical characteristics of HNSCC patients.
Patient
number Sex/Age Specimen type Diagnosis (tissues) Grade TNM Stage Mets
1 M/59 Tongue/Lymph nodes NAT/Tumor/Mets G3 T4aN1M0 IVA 1/9
2 M/63 Laryngopharynx/Lymph nodes NAT/Tumor/Mets G3 T3N2M0 IVA 9/9
3 M/56 Larynx/Lymph nodes NAT/Tumor/Mets G3 T2N2M0 IVA 5/11
4 M/61 Larynx/Lymph nodes NAT/Tumor/Mets G2 T3N2cM0 IVA 5/19
5 M/60 Hypopharynx/Lymph nodes NAT/Tumor/Mets G3 T3N2bM0 IVA 3/7
6 M/54 Larynx/Lymph nodes NAT/Tumor/Mets G1 T3N2M0 IVA 12/37
798 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
ADAM17-Mediated CD44 Cleavage, Stemness P. Kamarajan et al.
of integrin receptors, death receptors, adhesion molecules,
and complex signaling cascades can lead to anoikis resis-
tance and spread of metastatic cancer cells [22, 23, 42–
45].
CD44 is a multifunctional protein involved in cell
adhesion, migration, apoptosis resistance, drug resistance,
and recently stemness. CD44 is a primary receptor for
HA, a major component of the ECM, and it plays a criti-
cal role in cell signaling and cell-ECM interactions in
cancer [46–48]. In fact, expression of various CD44 pro-
tein variants correlates with aggressive human cancers,
including HNSCC and breast cancer [49]. Recent studies
showed that CD44 overexpression serves as a prognostic
factor in HNSCC and it is also associated with poor
prognosis in HNSCC [6, 50–52]. Importantly, it has been
proposed that cancer-initiating cells (cancer stem cells)
constitute a minor population of cells within a tumor,
and these stem cells can initiate the formation of new
tumors [6, 53] and possess the capacity to metastasize
[54]. These cells, including those in HNSCC, are enriched
with CD44 expression [5, 55, 56]. Thus, CD44 is believed
to be a stem cell marker in head and neck cancer as in
other cancers [15, 57]. Our findings provide new evi-
dence that CD44 cleavage plays an important role in
mediating stemness in HNSCC. Our initial finding that
CD44 cleavage was increased in HNSCC oraspheres com-
pared to the control/adherent HNSCC cell counterparts
led us to hypothesize that CD44 cleavage may play an
important role in regulating stemness. Specifically, cleav-
age of CD44 could promote disruption of cell-ECM con-
tacts and promote cell–cell contacts that drive sphere
formation. Thus, to further explore the relevance of
increased CD44 cleavage in the process of sphere forma-
tion, we used an inhibitor to ADAM17, a major protease
known to cleave CD44. This inhibitor has been used to
inhibit CD44 cleavage in several types of cancer [32].
Furthermore, ADAM17 itself has been implicated in regu-
lating tumorigenesis via mechanisms that include target-
ing and inhibition of a Sox9/ADAM17 Axis by miR145.
This mechanism also seems to involve release/activation
of IL-6 and epidermal growth factor receptor (EGFR)-
phosphoinositide 3-kinase (PI3K/AKT) [58, 59]. In agree-
ment with these studies, inhibiting ADAM17 activity or
expression also blocked HNSCC orasphere formation in
our in vitro assays and tumorigenesis in our in vivo
model. These findings indicate that CD44 cleavage by
ADAM17 is critical to the process of stemness and
HNSCC tumorigenesis.
The specific cleavage or shedding of CD44 into several
fragments and their biological significance has been the
focus of several studies. In a review by Nagano and Saya
[31], several important and relevant topics were discussed
including the fact that ectodomain cleavage of CD44 is
highly prevalent in human tumors, that the soluble form
of CD44 affects the function of membrane-bound CD44,
that ectodomain cleavage of CD44 is regulated by various
stimuli and metalloproteinases, and that CD44 cleavage
plays a role in CD44-dependent transcriptional activity
and cell migration. Recent studies by this group have
focused on the important role of ADAM17-mediated
cleavage of CD44 in oral SCC metastasis and invasion
[32, 33]. Others have also found an important relation-
ship between invasive ulcerative colitis carcinoma and
CD44 cleavage [60]. These studies are consistent with our
findings on the important role of CD44 cleavage in pro-
moting stemness and tumorigenesis.
In conclusion, our findings demonstrate that CD44
cleavage by ADAM17 promotes orasphere formation or
stemness and HNSCC tumorigenesis. While monoclonal
antibodies against specific CD44 isoforms have been
tested in patients with HNSCC for potential imaging or
targeting therapy against tumors [61], our data support
the notion that therapeutic pharmaceuticals that target
CD44 cleavage mechanisms within the stem cell compart-
ment can impair stemness and thus hold promise for
treating aggressive oral cancer.
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Figure 6. ADAM17 expression and CD44 cleavage are concomitantly elevated in human head and neck squamous cell carcinoma (HNSCC) tissue
specimens. Immunoblots showing the levels of CD44 cleavage and ADAM17 expression in HNSCC tissue specimens (N, normal adjacent tissue; T,
primary tumor; M, metastatic tissue), normalized to b-actin. Fold change in CD44 and ADAM17 expression in primary and metastatic tumors
relative to normal adjacent tissues was assessed using densitometric analysis.
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